An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis
Study of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis
Sponsor: Blueprint Medicines Corporation
Enrolling: Male and Female Patients
IRB Number: AAAR9514
U.S. Govt. ID: NCT03580655
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety and effectiveness of avapritinib (also known as BLU-285) in individuals who have been diagnosed with aggressive systemic mastocytosis (ASM), Systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell Leukemia (MCL). Avapritinib is an experimental drug means that is is not yet known if this drug will help patients. Open label means that you and your study doctor know you will receive avapritinib. This study will be conducted at multiple centers in the United States, Canada, Europe, and Australia.
This study is closed
Investigator
Joseph Jurcic, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a diagnosis of ASM, SM-AHN, or MCL? Yes No
Have you ever received treatment with avapritinib before? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE